A A A

About Us

Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO).

Alimera Sciences’ management team has a strong track record of product discovery, development and revenue growth in the ophthalmic pharmaceutical industry and are dedicated and focused to making Alimera a leading ophthalmic pharmaceutical company. Our team has demonstrated expertise through the extensive development and commercialization of ophthalmic products. Our strategy behind Alimera is to:

  • Successfully commercialize ILUVIEN® fluocinolone acetonide intravitreal implant) 0.19 mg, which recently received FDA-approval in the United States for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.1 Learn More
  • ILUVIEN has also been granted marketing authorizations in Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom as “ILUVIEN® 190 micrograms intravitreal implant in applicator”, for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
  • Continue evaluating ILUVIEN for other potential ophthalmic indications. Learn More
  • Evaluate the use of NADPH Oxidase inhibitors for ophthalmic diseases
  • Pursue the development, license or acquisition of rights to potential ophthalmic drug delivery technologies and compounds.
  • Operate as an ethically driven company, recognizing our responsibility to others and the importance of having a positive impact on those with whom we interact.

For information about joining our team, please visit the Careers page to view our current openings.

Important Safety Information

  • Contraindications
    • ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.
    • ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.
    • ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product.

 

  • Warnings and Precautions
    • Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the intravitreal injection.
    • Use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.
    • Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

 

  • Adverse Reactions
    • In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.